Globus Medical, Inc. $GMED Shares Sold by Sculptor Capital LP

Sculptor Capital LP cut its holdings in shares of Globus Medical, Inc. (NYSE:GMED) by 14.3% in the 4th quarter, Holdings Channel reports. The fund owned 3,000,000 shares of the medical device company’s stock after selling 500,000 shares during the period. Globus Medical accounts for about 2.7% of Sculptor Capital LP’s investment portfolio, making the stock its 5th biggest position. Sculptor Capital LP’s holdings in Globus Medical were worth $261,930,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the business. Vanguard Personalized Indexing Management LLC grew its stake in shares of Globus Medical by 18.7% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 16,188 shares of the medical device company’s stock valued at $1,413,000 after acquiring an additional 2,554 shares in the last quarter. Panagora Asset Management Inc. acquired a new stake in shares of Globus Medical during the fourth quarter valued at about $276,000. Fieldview Capital Management LLC acquired a new stake in shares of Globus Medical during the fourth quarter valued at about $3,316,000. Horizon Investment Services LLC acquired a new stake in shares of Globus Medical during the fourth quarter valued at about $1,538,000. Finally, Kennedy Capital Management LLC grew its stake in shares of Globus Medical by 0.3% during the fourth quarter. Kennedy Capital Management LLC now owns 492,641 shares of the medical device company’s stock valued at $43,012,000 after acquiring an additional 1,692 shares in the last quarter. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently weighed in on GMED. Wall Street Zen downgraded Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Piper Sandler lowered their target price on Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a research note on Monday. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a research note on Wednesday, April 15th. Truist Financial set a $115.00 target price on Globus Medical in a research note on Wednesday, February 25th. Finally, Barclays raised their target price on Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $105.00.

Insider Buying and Selling

In related news, Director David D. Davidar sold 25,000 shares of Globus Medical stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $80.76, for a total value of $2,019,000.00. Following the completion of the transaction, the director directly owned 510,175 shares in the company, valued at approximately $41,201,733. This trade represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 18.38% of the company’s stock.

Globus Medical Stock Performance

NYSE:GMED opened at $77.25 on Tuesday. The company has a market capitalization of $10.49 billion, a price-to-earnings ratio of 17.97, a price-to-earnings-growth ratio of 1.66 and a beta of 0.95. Globus Medical, Inc. has a one year low of $51.79 and a one year high of $101.40. The stock has a 50-day simple moving average of $85.56 and a 200 day simple moving average of $88.00.

Globus Medical (NYSE:GMED) last posted its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. The business had revenue of $759.85 million during the quarter, compared to the consensus estimate of $740.35 million. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The company’s revenue for the quarter was up 27.0% compared to the same quarter last year. During the same period last year, the firm earned $0.68 earnings per share. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, equities research analysts forecast that Globus Medical, Inc. will post 4.74 EPS for the current fiscal year.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.